WAYNE, Penn., March 25, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) (“Egalet”) today announced the initiation of the bioequivalence (BE) program for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the treatment of moderate to severe chronic pain. These studies are intended to establish bioequivalence of Egalet-001 to MS Contin® (morphine sulfate controlled-release) (“MS Contin”).
Help employers find you! Check out all the jobs and post your resume.
